JNJ 28431754
Showing 1 - 25 of 459
Diabetes Trial in India (Canagliflozin + Metformin HCl (Fixed Dose Combination))
Completed
- Diabetes Mellitus
- Canagliflozin + Metformin hydrochloride (Fixed Dose Combination)
-
Bengaluru, India
- +9 more
Aug 16, 2022
Heart Failure Trial in United States (Canagliflozin 100 mg, Placebo)
Completed
- Heart Failure
- Canagliflozin 100 mg
- Placebo
-
Fort Smith, Arkansas
- +17 more
Dec 20, 2022
Diabetes, Type 2 Trial in Worldwide (Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo)
Recruiting
- Diabetes Mellitus, Type 2
- Canagliflozin 100 mg
- +2 more
-
Little Rock, Arkansas
- +121 more
Aug 18, 2022
Healthy Trial in Miramar (Canagliflozin (JNJ-28431754), Placebo)
Completed
- Healthy
- Canagliflozin (JNJ-28431754)
- Placebo
-
Miramar, Florida(unnamed)
Dec 11, 2018
Diabetes, Type 2 Trial in Guadalajara, Mexico City, Monterrey (Canagliflozin 300 mg, Sitagliptin 100 mg, Metformin)
Completed
- Diabetes Mellitus, Type 2
- Canagliflozin 300 mg
- +2 more
-
Guadalajara, Mexico
- +4 more
Nov 11, 2019
Advanced Prostate Cancer Trial in Lyon, Villejuif, Rotterdam (JNJ-78278343, JNJ-87189401)
Not yet recruiting
- Advanced Prostate Cancer
-
Lyon, France
- +2 more
Oct 18, 2023
Myeloproliferative Disorders, Essential Thrombocythemia, Tumors Trial (JNJ-88549968)
Not yet recruiting
- Myeloproliferative Disorders
- +3 more
- (no location specified)
Nov 21, 2023
Metastatic Castration-resistant Prostate Tumors Trial in Australia, Korea, Republic of, United States (JNJ-78278343, Cetrelimab)
Not yet recruiting
- Metastatic Castration-resistant Prostate Neoplasms
-
Sarasota, Florida
- +7 more
Apr 6, 2023
Prostatic Tumors, Metastatic Castration-Resistant Prostate Cancer Trial in Worldwide (Abiraterone Acetate, Prednisone,
Active, not recruiting
- Prostatic Neoplasms
- Metastatic Castration-Resistant Prostate Cancer
- Abiraterone Acetate
- +2 more
-
Los Angeles, California
- +6 more
Jan 18, 2023
Multiple Myeloma Trial in Belgium, Israel, Spain (Daratumumab, JNJ-63723283)
Completed
- Multiple Myeloma
-
Antwerpen, Belgium
- +12 more
Dec 1, 2022
Healthy Trial in Leiden (JNJ-69095897, Placebo)
Recruiting
- Healthy
- JNJ-69095897
- Placebo
-
Leiden, NetherlandsCentre for Human Drug Research
Jan 31, 2023
Relapsed or Refractory Multiple Myeloma Trial in Worldwide (JNJ-79635322)
Recruiting
- Relapsed or Refractory Multiple Myeloma
-
Edegem, Belgium
- +16 more
Jan 27, 2023
Carcinoma, Non-small-Cell Lung Trial in New York, Fairfax (JNJ-86974680, Cetrelimab, Radiation Therapy)
Recruiting
- Carcinoma, Non-small-Cell Lung
- JNJ-86974680
- +2 more
-
New York, New York
- +1 more
Nov 8, 2023
Multiple Myeloma Trial in Japan, United States (JNJ-68284528)
Completed
- Multiple Myeloma
- JNJ-68284528
-
Phoenix, Arizona
- +20 more
Oct 5, 2022
Geographic Atrophy, Macular Degeneration Trial in United States (JNJ-81201887, Prednisone, Placebo)
Recruiting
- Geographic Atrophy
- Macular Degeneration
- JNJ-81201887
- +4 more
-
Phoenix, Arizona
- +3 more
Mar 31, 2023